Could this growth company with no debt and high profit margins become a 10 bagger in the future? Stock was upgraded to a buy by a few firms today. Financials look pretty darn good from what I can see or could I be missing something? Would like any feedback to decide if its worth pursuing.
Thanks,
Tony
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
In addition to what you’ve said, I can see a formidable market niche for what the company does. It’s also welcoming to see an IPO that doesn’t collapse on itself in a just a few days and hope it stays that way. I, too, am hoping for feedback from an expert in the medical field.
Minimal invasive treatment that shows immediate results from what the company says. The treatments are also FDA approved. Very low share float as well. Seems the company is managed very well could be a great add to anyone’s portfolio in my opinion. Hope Travis takes a look at it and gives some valuable feedback.
Looks pretty impressive, though I don’t know anything about the products… certainly spending on noninvasive aesthetics is still awfully strong (last time I saw a stock like this touted, it was not long before Allergan bought out Zeltiq, which makes the CoolSculpting system).
Haven’t looked at the financials, but they are reporting strong revenue growth — is it a machine? Do they have the basic razor&blade model? If so, I’d be willing to think about it given the fact that they’re profitable and already growing earnings, even though they’re probably priced at more than 30X this year’s likely earnings (analysts likely won’t be publishing estimates for a while, since they just went public a couple weeks ago). Could be an opportunity, particularly if there’s a lot of insider selling at lockup (usually six months post-IPO), though I haven’t looked for skeletons and I hate to jump too aggressively on a new and “hot” IPO.
INMD is in Motley Fool’s Firecracker service now.
Oops I meant Biotech Breakthroughs